Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 23,09:00-12:00
Merits & Tree Law Offices Session:From IP to BD: China Innovative Drug Transaction Competency
Stay tuned
Meeting Planner
Tang Huadong:Partner, Merits & Tree Law Offices
Zhu Pengcheng:Founder & CEO, ATLATL Innovation Center
Guo Xiaoxing:Partner, Merits & Tree Law Offices
Huang Xiaolin(Moderator):Partner, Merits & Tree Law Offices
09:00-09:05 Opening Remarks: Why the Shift from IP to BD Deal-Making Capability Matters
Tang Huadong:Partner, Merits & Tree Law Offices
09:05-09:20 Keynote I: From IP to BD — The Six Core Drivers of Deal-Making Power in China's Innovative Drug Transactions
Tang Huadong:Partner, Merits & Tree Law Offices
09:20-09:40 Keynote II: Accelerating the IP-to-BD Journey with a "Super-Server" — ATLATL's Engineering Practice
Zhu Pengcheng:Founder & CEO, ATLATL Innovation Center
09:40-10:00 Keynote III: Compliance Red Lines in Innovative Drug BD Transactions
Guo Xiaoxing:Partner, Merits & Tree Law Offices
10:00-10:20 Keynote IV: IP Challenges and Opportunities for Innovators in a Highly Competitive Landscape
Lao Fang:IP Director, METiS TechBio
10:20-10:40 Keynote V: Business Development and Global Partnership Pathways for Chinese Biotech Enterprises
Eric Li: Managing Director & Head of China, Locust Walk
10:40-10:45 Transition: BD Deal-Making Capability Assessment Portal
Tang Huadong:Partner, Merits & Tree Law Offices
10:45-11:50 Panel Discussion: From BP to Term Sheet — Key Bottlenecks and Breakthrough Paths in Chinese Innovative Drug BD Transactions
Moderator:
Huang Xiaolin : Partner, Merits & Tree Law Offices
Panelists:
Du Shanshan:China Regulatory Affairs Director, Servier
Guo Lianyu:External Innovation Director, R&D, Servier
Guo Songxi:Head of IP, Astellas China
David Miao:Chairman & CEO, Imbioray Biopharm Chief Scientific Advisor, Hangzhou Adcoris BioPharma
11:50-12:00 Summarize
Tang Huadong:Partner, Merits & Tree Law Offices